Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pepgen Inc (PEPG)

Pepgen Inc (PEPG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 292,356
  • Shares Outstanding, K 69,115
  • Annual Sales, $ 0 K
  • Annual Income, $ -89,660 K
  • EBIT $ -94 M
  • EBITDA $ -91 M
  • 60-Month Beta 1.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.11

Options Overview Details

View History
  • Implied Volatility 148.86% (-476.80%)
  • Historical Volatility 259.69%
  • IV Percentile 18%
  • IV Rank 14.55%
  • IV High 828.50% on 09/17/25
  • IV Low 33.17% on 09/05/25
  • Expected Move (DTE 17) 0.38 (21.61%)
  • Put/Call Vol Ratio 0.25
  • Today's Volume 8,260
  • Volume Avg (30-Day) 806
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 6,595
  • Open Int (30-Day) 8,711
  • Expected Range 1.39 to 2.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 5
  • High Estimate $-0.27
  • Low Estimate $-0.41
  • Prior Year $-0.92
  • Growth Rate Est. (year over year) +66.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.32 +34.09%
on 03/31/26
6.78 -73.89%
on 03/04/26
-4.45 (-71.54%)
since 02/27/26
3-Month
1.32 +34.09%
on 03/31/26
7.80 -77.31%
on 01/02/26
-4.04 (-69.54%)
since 12/26/25
52-Week
0.88 +101.11%
on 04/09/25
7.80 -77.31%
on 01/02/26
+0.29 (+19.59%)
since 03/28/25

Most Recent Stories

More News
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported – – Mean splicing correction of 7.3% observed...

PEPG : 1.77 (-58.16%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK , March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG).  Such investors are advised to contact...

PEPG : 1.77 (-58.16%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK , March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG).  Such investors are advised to contact...

PEPG : 1.77 (-58.16%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK , March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. ("PepGen" or the "Company") (NASDAQ: PEPG).  Such investors are advised to contact...

PEPG : 1.77 (-58.16%)
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights

– FREEDOM2-DM1 5 mg/kg cohort data expected in Q1 2026 – – Patient dosing in the FREEDOM2 10 mg/kg cohort is proceeding in Canada and the UK, with data expected...

PEPG : 1.77 (-58.16%)
PepGen Announces Regulatory Updates on FREEDOM2

- U.S. FDA places FREEDOM2 trial on partial clinical hold related to preclinical pharmacology and toxicology - - Received regulatory clearance to initiate FREEDOM2 in South Korea, Australia, and...

PEPG : 1.77 (-58.16%)
PepGen to Participate in the Leerink Global Healthcare Conference

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 1.77 (-58.16%)
PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Business and Legal Officer

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 1.77 (-58.16%)
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological...

PEPG : 1.77 (-58.16%)
PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

Composition of matter patent covers the Company’s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio

PEPG : 1.77 (-58.16%)

Business Summary

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 2.89
2nd Resistance Point 2.48
1st Resistance Point 2.13
Last Price 1.77
1st Support Level 1.37
2nd Support Level 0.96
3rd Support Level 0.61

See More

52-Week High 7.80
Fibonacci 61.8% 5.16
Fibonacci 50% 4.34
Fibonacci 38.2% 3.52
Last Price 1.77
52-Week Low 0.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.